SCHEMBL14366290

SCHEMBL14366290

C/N=C(/NC)NCCCC(NC(=O)c1ccccc1)C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ C3AR1 Q16581 2/20 0.46
▸ PDE4A P27815 3/20 0.45
▸ PDE4B Q07343 2/20 0.45
▸ PDE4C Q08493 2/20 0.45
▸ PDE4D Q08499 2/20 0.45
▸ PADI1 Q9ULC6 2/20 0.45
▸ PADI4 Q9UM07 2/20 0.45
▸ PADI2 Q9Y2J8 2/20 0.45
▸ PADI6 Q6TGC4 1/20 0.45
▸ PADI3 Q9ULW8 1/20 0.45
▸ ALB P02768 1/20 0.45
▸ FOLH1 Q04609 8/20 0.44
▸ SCN5A Q14524 1/20 0.44
▸ SCN2A Q99250 1/20 0.44
▸ CA2 P00918 1/20 0.44
▸ KISS1R Q969F8 1/20 0.42
▸ ITGB1 P05556 1/20 0.42
▸ ITGA5 P08648 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8975695 0.83 FOLH1 (0.59) FOLH1
SCHEMBL10801725 0.83 FOLH1 (0.59) FOLH1
SCHEMBL14366288 0.82 FOLH1 (0.46) C3AR1PDE4APDE4BPDE4CPDE4D
SCHEMBL12560085 0.80 FOLH1 (0.47) C3AR1PDE4APDE4BPDE4CPDE4D
SCHEMBL1983969 0.80 FOLH1 (0.47) C3AR1PDE4APDE4BPDE4CPDE4D
SCHEMBL15231556 0.79 C3AR1 (0.60) C3AR1PDE4APDE4BPDE4CPDE4D
SCHEMBL11544593 0.79 FOLH1 (0.60) FOLH1
SCHEMBL10801036 0.79 FOLH1 (0.60) FOLH1
SCHEMBL22509292 0.79 KDM1A (0.51) C3AR1FOLH1SCN5ASCN2A
SCHEMBL21196892 0.79 KDM1A (0.51) C3AR1FOLH1SCN5ASCN2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070276040-A1 Peptidyl Arginine Deiminase Type IV Inhibitor YOKOHAMA CITY UNIVERISITY (JP) 2007-11-29 — — US disclosed
US-20070276040-A1 Peptidyl Arginine Deiminase Type IV Inhibitor YOKOHAMA CITY UNIVERISITY (JP) 2007-11-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070276040-A1 Peptidyl Arginine Deiminase Type IV Inhibitor PADI4, PADI1, PADI2 C3AR1 581/4885PDE4A 75/4885PDE4B 106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback